Recurrence and prognostic factors in borderline ovarian tumors

被引:66
作者
Ayhan, A
Guven, ESG
Guven, S
Kucukali, T
机构
[1] Hacettepe Univ, Fac Med, Div Gynecol Oncol, Dept Obstet & Gynecol, Ankara, Turkey
[2] Etlik Womens Hlth & Teaching Hosp, Dept Obstet & Gynecol, Ankara, Turkey
[3] Hacettepe Univ, Fac Med, Dept Pathol, TR-06100 Ankara, Turkey
关键词
borderline ovarian tumors; prognostic factors; recurrence; surgery;
D O I
10.1016/j.ygyno.2005.05.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The purpose of this study was to evaluate the survival estimates and clinico-pathological variables in patients treated for borderline ovarian tumors. Methods. The patients treated for borderline ovarian tumors were evaluated retrospectively. Data were obtained from hospital records and special gynecologic oncology forms. Results. Overall, 100 patients were evaluated. The mean age at the time of diagnosis was 41.7 (range, 19-84). Seventy one (71%) patients underwent surgical staging including 49 (49%) of them with comprehensive surgical staging, 22 (22%) with fertility-sparing surgery. Only 30 (30%) patients were unstaged. The histopathological diagnosis was serous, mucinous, and the other types of borderline ovarian tumor in 54 (54%), 39 (39%), and 7 (7%) of the patients, respectively. Seventy patients had stage IA (70%), 10 had stage IB (10%), 9 had stage IC (9%), 3 had stage IIIA (3%), and 8 had stage IIIC (8%) disease. The stage of only four patients in which disease confined to ovary was upgraded as stage IIIC following surgical staging procedure. The recurrence rate was found 3% (3). The overall disease-free survival rates of BOT in surgically staged (comprehensive, fertility-sparing surgery) and unstaged patients were 97.92%, 95.00%, and 96.30%, respectively. But, the overall tumor-free survival was significantly found to be decreased in cases of young age (< 30 years old), performing fertility-sparing surgery and presence of micropapillary architecture or peritoneal implants. Overall survival rates of BOT in surgically staged (comprehensive, fertility-sparing surgery) and unstaged patients were 97.9%, and 100% and 100%, respectively. Conclusion. Low malignant potential ovarian tumors have excellent survival, and the patients can be treated safely by conservative surgery. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:439 / 445
页数:7
相关论文
共 46 条
[1]  
[Anonymous], 1987, Am J Obstet Gynecol, V156, P263
[2]  
BARAKAT RR, 1994, OBSTET GYN CLIN N AM, V21, P93
[3]   PLATINUM-BASED CHEMOTHERAPY FOR ADVANCED-STAGE SEROUS OVARIAN-CARCINOMA OF LOW MALIGNANT POTENTIAL [J].
BARAKAT, RR ;
BENJAMIN, I ;
LEWIS, JL ;
SAIGO, PE ;
CURTIN, JP ;
HOSKINS, WJ .
GYNECOLOGIC ONCOLOGY, 1995, 59 (03) :390-393
[4]   PRELIMINARY-ANALYSIS OF THE BEHAVIOR OF STAGE-I OVARIAN SEROUS TUMORS OF LOW MALIGNANT POTENTIAL - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY [J].
BARNHILL, DR ;
KURMAN, RJ ;
BRADY, MF ;
OMURA, GA ;
YORDAN, E ;
GIVEN, FT ;
KUCERA, PR ;
ROMAN, LD .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (11) :2752-2756
[5]   Epithelial ovarian tumors of low malignant potential: The role of microinvasion [J].
Buttin, BM ;
Herzog, TJ ;
Powell, MA ;
Rader, JS ;
Mutch, DG .
OBSTETRICS AND GYNECOLOGY, 2002, 99 (01) :11-17
[6]   Lymph node disorders and prognostic value of nodal involvement in patients treated for a borderline ovarian tumor:: An analysis of a series of 42 lymphadenectomies [J].
Camatte, S ;
Morice, P ;
Atallah, D ;
Pautier, P ;
Lhommé, C ;
Haie-meder, C ;
Duvillard, P ;
Castaigne, D .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2002, 195 (03) :332-338
[7]  
CARNATTE S, 2002, BJOG, V109, P376
[8]   COLOR DOPPLER ULTRASONOGRAPHY AND SERUM CA-125 IN THE DIFFERENTIATION OF BENIGN AND MALIGNANT OVARIAN-TUMORS [J].
CHOU, CY ;
CHANG, CH ;
YAO, BL ;
KUO, HC .
JOURNAL OF CLINICAL ULTRASOUND, 1994, 22 (08) :491-496
[9]   Surgical response of advanced-stage borderline ovarian tumors to paclitaxel and cisplatin chemotherapy [J].
Eltabbakh, GH ;
Srivastava, A ;
Garafano, LL .
GYNECOLOGIC ONCOLOGY, 2000, 77 (02) :343-344
[10]   Clinical management potential tumours of low malignancy [J].
Gershenson, DM .
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2002, 16 (04) :513-+